Is BSX a good stock to buy? We came across a bullish thesis on Boston Scientific Corporation on Guardian Research’s Substack. In this article, we will summarize the bulls’ thesis on BSX. Boston Scientific Corporation’s share was trading at $69.48 as of March 20th. BSX’s trailing and forward P/E were 35.81 and 20.12 respectively according to Yahoo Finance.
sfam_photo/Shutterstock.com
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. As a global leader in medical devices, BSX operates through its MedSurg and Cardiovascular segments, generating $20.1 billion in 2025 revenue and demonstrating strong organic growth across its core businesses.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Despite a recent 17.5% one-day selloff following Q4 2025 earnings, the pullback reflects short-term concerns over the Electrophysiology division missing expectations and cautious 2026 guidance, rather than fundamental weakness. Core operations are robust, with Cardiovascular reporting 18.2% growth and full-year net sales up nearly 20%, while adjusted EPS grew 22% year-over-year.
BSX’s growth trajectory is underpinned by multiple catalysts. Pulse Field Ablation (FARAPULSE) continues to gain adoption in atrial fibrillation treatment, WATCHMAN devices provide an emerging growth opportunity through left atrial appendage closure, and the Penumbra acquisition strengthens the company’s high-growth MedTech portfolio.
Concerns about GLP-1 therapies slowing cardiovascular demand are overblown, as structural cardiac conditions and genetic factors maintain persistent need for BSX’s solutions. Financially, the company trades at a PEG ratio of 0.93, offering attractive growth at a discount compared to peers like Stryker and Intuitive Surgical, while EV/Revenue-to-Growth metrics support its relative undervaluation.
Technically, BSX remains above its 200-week moving average, confirming a long-term secular bull trend, and the recent pullback positions the stock near historically strong buying zones. Macro tailwinds, including policy immunity from managed care reimbursement risk, global demand from aging populations, and potential declining interest rates, further support growth. BSX is projected with a target price of $130, implying 71% upside, driven by temporary EP underperformance, WATCHMAN data catalysts, Penumbra integration, and a re-rating toward historical PEG multiples, making BSX a strong buy across all time horizons.
Previously, we covered a bullish thesis on Boston Scientific Corporation (BSX) by Magnus Ofstad in April 2025, which highlighted the company’s leadership in minimally invasive medical devices, innovation with Watchman and Farapulse, disciplined acquisitions, and high-margin global growth. BSX’s stock price has depreciated by approximately 26.29% since our coverage due to increased competetive pressures and the Electrophysiology division missing expectations with cautious 2026 guidance. Guardian Research shares a similar view but emphasizes near-term catalysts like the EP miss, WATCHMAN data, and Penumbra integration.
Boston Scientific Corporation is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 110 hedge fund portfolios held BSX at the end of the fourth quarter which was 102 in the previous quarter. While we acknowledge the risk and potential of BSX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BSX and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
